EntryPoint Capital LLC Acquires New Holdings in Artivion, Inc. $AORT

Key Points

• EntryPoint Capital LLC has acquired a new stake in Artivion, Inc., purchasing 11,565 shares valued at approximately $284,000 during the first quarter.
• A number of institutional investors, including Wellington Management Group LLC and American Century Companies Inc., have increased their holdings in Artivion, contributing to an overall institutional ownership of 86.37% in the company.
• Artivion's earnings report showed earnings per share of $0.24 for the quarter, significantly beating the consensus estimate of $0.11, along with a revenue increase of 15.3% compared to the same quarter last year.

EntryPoint Capital LLC acquired a new stake in shares of Artivion, Inc. (NYSE:AORT - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,565 shares of the company's stock, valued at approximately $284,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its position in Artivion by 4.1% during the first quarter. Wellington Management Group LLP now owns 1,727,408 shares of the company's stock valued at $42,460,000 after purchasing an additional 67,327 shares during the period. American Century Companies Inc. increased its holdings in Artivion by 14.9% during the first quarter. American Century Companies Inc. now owns 66,406 shares of the company's stock valued at $1,632,000 after buying an additional 8,635 shares during the last quarter. Lord Abbett & CO. LLC increased its holdings in Artivion by 31.0% during the first quarter. Lord Abbett & CO. LLC now owns 401,904 shares of the company's stock valued at $9,879,000 after buying an additional 95,202 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Artivion by 17.5% during the first quarter. Russell Investments Group Ltd. now owns 169,594 shares of the company's stock valued at $4,169,000 after buying an additional 25,234 shares during the last quarter. Finally, Public Sector Pension Investment Board increased its holdings in Artivion by 27.4% during the first quarter. Public Sector Pension Investment Board now owns 119,650 shares of the company's stock valued at $2,941,000 after buying an additional 25,698 shares during the last quarter. Institutional investors own 86.37% of the company's stock.

Analyst Ratings Changes

A number of brokerages have commented on AORT. JMP Securities upped their target price on shares of Artivion from $33.00 to $42.00 and gave the company a "market outperform" rating in a report on Friday, August 8th. Canaccord Genuity Group upped their target price on shares of Artivion from $35.00 to $41.00 and gave the company a "buy" rating in a report on Friday, August 8th. Wall Street Zen cut shares of Artivion from a "buy" rating to a "hold" rating in a report on Sunday, August 17th. LADENBURG THALM/SH SH cut shares of Artivion from a "buy" rating to a "neutral" rating and upped their target price for the company from $32.00 to $38.80 in a report on Wednesday, August 13th. Finally, Oppenheimer reaffirmed an "outperform" rating on shares of Artivion in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, Artivion has an average rating of "Buy" and a consensus target price of $40.63.

Insider Activity at Artivion

In related news, CEO James P. Mackin sold 12,500 shares of the firm's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $42.32, for a total transaction of $529,000.00. Following the completion of the transaction, the chief executive officer directly owned 852,783 shares of the company's stock, valued at approximately $36,089,776.56. This trade represents a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Marshall S. Stanton sold 26,132 shares of the firm's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $28.44, for a total transaction of $743,194.08. Following the transaction, the senior vice president directly owned 79,200 shares of the company's stock, valued at $2,252,448. The trade was a 24.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 96,538 shares of company stock valued at $3,444,651. Insiders own 7.60% of the company's stock.

Artivion Stock Performance

Shares of NYSE AORT opened at $44.8140 on Friday. The firm has a fifty day moving average price of $33.65 and a 200-day moving average price of $28.87. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. The stock has a market cap of $2.11 billion, a PE ratio of -106.70 and a beta of 1.64. Artivion, Inc. has a 1 year low of $21.97 and a 1 year high of $45.07.

Artivion (NYSE:AORT - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.13. The company had revenue of $112.97 million during the quarter, compared to analysts' expectations of $107.96 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The firm's revenue was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. Equities analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

Want to see what other hedge funds are holding AORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Artivion, Inc. (NYSE:AORT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.